focus -WSS

focus

author：Wikipedia 2025-09-29 04:03:17 Page View：74485

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne patients, backed by ‘dark money’ group, to debate drug prices
Next article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban

leisure time

Affirmative action in medical school literally saved lives

AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

STEFANIREYNOLDS/AFPviaGettyImagesUnderstandhowscience,healthpolicy,andmedicineshapetheworldeveryday.

Anesthesiologist group: stop taking Ozempic before surgery

EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

ChristineKao/STATTheFoodandDrugAdministration’sapprovalonFridayoftwogenetherapiesforsicklecelldiseas

focus

comprehensive

leisure time

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition